Skip to content
Triangle logo TriangleGet started
← Study library

NCT00807768 · REGISTRY CONDITION SEARCH

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
UNKNOWN
Registry last update
2019-03-20

This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether pelvic radiation therapy alone is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Recurrence or Death Events at Primary Analysis

→

outcome · POSTED

Number of Participants With Death Events

→

outcome · POSTED

Number of Participants With Sites of Recurrence

→

outcome · POSTED

Patient Reported Fatigue

→

outcome · POSTED

Patient-reported Neurotoxicity

→

outcome · POSTED

Patient-reported Quality of Life

→

outcome · NOT POSTED

Gene Expression Based Risk Score

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * To be considered eligible to participate in this trial, all patients must have undergone hysterectomy; bilateral salpingo-oophorectomy (open or laparoscopic approach) is strongly encouraged * Peritoneal cytology should be obtained on entering the peritoneal cavity, as described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual (https://gogmember.gog.org/manuals/pdf/surgman.pdf); pelvic and para-aortic lymphadenectomy are optional, but strongly encouraged (as staged patients enrolled on GOG-0210-molecular markers in endometrial carcinoma are eligible for this study) * The procedures may be performed via laparotomy or laparoscopy (including robot-assisted) as per the surgeon?s preference; the surgeon must record in the operative report whether a lymphadenectomy was performed (see link above to Surgical Procedures Manual) or not; a specific number of lymph nodes removed will not be utilized for eligibility, but the operative report should reflect that the procedure performed was consistent with the procedures described in the GOG Surgical Manual * If either a bilateral salpingo-oophorectomy or nodal dissection was not performed, post-operative pre-treatment computed tomography (CT)/magnetic resonance imaging (MRI) is required and must not demonstrate evidence suggestive of metastatic disease (adnexa, nodes, intraperitoneal disease); post-operative, pre-treatment CT/MRI must be performed if a pelvic and para-aortic nodal dissection was not performed * For the purposes of description, patients will be staged according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system; eligibility is defined based on clinical-pathologic features; patients with endometrial carcinoma (endometrioid types) confined to the corpus uteri or with endocervical glandular involvement fitting one of the following high-intermediate risk factor categories: * Age \>= 70 years with one risk factor * Age \>= 50 with 2 risk factors * Age \>= 18 years with 3 risk factors * Risk factors: grade 2 or 3 tumor, (+) lymphovascular space invasion, outer ? myometrial invasion; patients with these risk criteria may be enrolled with either positive or negative cytology * Patients with stage II endometrial carcinoma (any histology) with cervical stromal invasion (occult or gross involvement), with or without high-intermediate risk factors * Patients with serous or clear cell histology (with or without other high-intermediate risk factors) are eligible provided the disease is uterine-confined (with or without cervical stromal invasion or endocervical glandular involvement), and with peritoneal cytology negative for malignancy * Patients must have GOG performance status 0, 1, or 2 * Absolute neutrophil count (ANC) \>= 1,500/mcl (equivalent to Common Toxicity Criteria \[CTCAE version \[v\] 3.0\] grade 1) * Platelets \>= 100,000/mcl (CTCAE v3.0 grade 0-1) * Serum creatinine =\< institutional upper limit normal (ULN), CTCAE v 3.0 grade 0 * Note: If serum creatinine \> ULN, a 24-hour creatinine clearance must be collected and must be \> 50 mL/min * Bilirubin =\< 1.5 x ULN (CTCAE v3.0 grade 1) * Serum glutamic oxaloacetic transaminase (SGOT) =\< 2.5 x ULN (CTCAE grade 0-1) * Alkaline phosphatase =\< 2.5 x ULN (CTCAE grade 0-1) * Neuropathy (sensory and motor) =\< CTCAE v3.0 grade 1 * Patients who have met the pre-entry requirements; testing values/results must meet eligibility criteria * Patients must have signed an approved informed consent and authorization permitting release of personal health information Exclusion Criteria: * Patients who have already received non-surgical therapy for endometrial cancer including chemotherapy, radiation (example, pre-operative or post-operative brachytherapy), hormonal or biologic therapy * Patients identified with pathologically confirmed spread of cancer beyond the uterus and cervix to pelvic or para-aortic lymph nodes, adnexal structures, and/or other anatomic sites, or patients with serous or clear cell histology and with positive cytologic washings * Patients with nodal (for patients who did not have nodal dissection performed) or distant disease determined based on imaging studies; patients with suspicious nodes that have been biopsied (re-staging operation, fine needle aspiration \[FNA\]) and are pathologically negative will be eligible * Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years; patients are excluded if their previous cancer treatment contraindicates this protocol therapy; specifically, patients who have received prior radiotherapy directed to treat disease within the abdominal cavity or pelvis are excluded * Prior radiation of localized cancer of the breast, head and neck, thyroid, or skin is permitted, provided that it was completed more than 5 years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than 5 years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients who have contraindications to pelvic radiation therapy (RT) (e.g. pelvic kidney, connective tissue disease, inflammatory bowel disease, etc.) should be screened in advance and not be considered eligible for the trial * Patients with recurrent endometrial cancer * Patients with surgical or clinical, FIGO 2009 stage III or IV endometrial carcinoma * Patients with non-epithelial uterine malignancies such as uterine carcinosarcoma or leiomyosarcoma
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
    intervention Names
    1. Radiation: 3-Dimensional Conformal Radiation Therapy
    2. Radiation: Intensity-Modulated Radiation Therapy
    3. Radiation: Internal Radiation Therapy
    4. Other: Laboratory Biomarker Analysis
    5. Other: Quality-of-Life Assessment
    6. Other: Questionnaire Administration
    label
    Arm I (pelvic radiation therapy)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Carboplatin
    2. Radiation: Internal Radiation Therapy
    3. Other: Laboratory Biomarker Analysis
    4. Drug: Paclitaxel
    5. Other: Quality-of-Life Assessment
    6. Other: Questionnaire Administration
    label
    Arm II (brachytherapy, paclitaxel, carboplatin)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    description
    Undergo pelvic radiation therapy
    name
    3-Dimensional Conformal Radiation Therapy
    other Names
    1. 3-dimensional radiation therapy
    2. 3D CONFORMAL RADIATION THERAPY
    3. 3D CRT
    4. 3D-CRT
    5. Conformal Therapy
    6. Radiation Conformal Therapy
    type
    RADIATION
  2. arm Group Labels
    1. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Given IV
    name
    Carboplatin
    other Names
    1. Blastocarb
    2. Carboplat
    3. Carboplatin Hexal
    4. Carboplatino
    5. Carbosin
    6. Carbosol
    7. Carbotec
    8. CBDCA
    9. Displata
    10. Ercar
    11. JM-8
    12. Nealorin
    type
    DRUG
  3. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    description
    Undergo pelvic radiation therapy
    name
    Intensity-Modulated Radiation Therapy
    other Names
    1. IMRT
    2. Intensity Modulated RT
    3. Intensity-Modulated Radiotherapy
    type
    RADIATION
  4. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    2. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Undergo vaginal cuff brachytherapy
    name
    Internal Radiation Therapy
    other Names
    1. BRACHYTHERAPY
    2. internal radiation
    3. Internal Radiation Brachytherapy
    4. Radiation Brachytherapy
    type
    RADIATION
  5. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    2. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  6. arm Group Labels
    1. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Given IV
    name
    Paclitaxel
    other Names
    1. Anzatax
    2. Asotax
    3. Bristaxol
    4. Praxel
    5. Taxol
    6. Taxol Konzentrat
    type
    DRUG
  7. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    2. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Ancillary studies
    name
    Quality-of-Life Assessment
    other Names
    1. Quality of Life Assessment
    type
    OTHER
  8. arm Group Labels
    1. Arm I (pelvic radiation therapy)
    2. Arm II (brachytherapy, paclitaxel, carboplatin)
    description
    Ancillary studies
    name
    Questionnaire Administration
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
601
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. measure
    Gene Expression Based Risk Score
    time Frame
    Baseline
primary Outcomes
  1. description
    Recurrence-Free Survival is the period from study entry until disease recurrence, death, or date of last contact
    measure
    Number of Participants With Recurrence or Death Events at Primary Analysis
    time Frame
    Within 4 weeks after completing or discontinuing study therapy, then every 6 months for 2 years, then annually for 3 years, then as clinically indicated, assessed up to 10 years
secondary Outcomes
  1. description
    The number of death events is reported. Overall survival is reported by the number of deaths occurring while on study.
    measure
    Number of Participants With Death Events
    time Frame
    Overall survival is measured from study enrollment for up to 10 years.
  2. description
    Three competing risk analyses were carried out for three different types of recurrences: 1) any vaginal, 2) any pelvic or any PA nodes and 3) any distant. More than one type of recurrence can be counted for an individual patient. A death prior to a specific type of recurrence was considered a competing event.
    measure
    Number of Participants With Sites of Recurrence
    time Frame
    Within 4 weeks after completing or discontinuing study therapy, then every 6 months for 2 years, then annually for 3 years, then as clinically indicated thereafter, up to 10 years
  3. description
    Patient reported fatigue as measured with the Functional Assessment of Chronic Illness Therapy- Fatigue scale (FACIT-Fatigue). The FACIT-Fatigue contains 13 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Fatigue score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The FACIT-Fatigue score ranges 0-52 with a large score suggests less fatigue.
    measure
    Patient Reported Fatigue
    time Frame
    Prior to study treatment (baseline), 4 weeks post the starting of study treatment, 10-11 weeks post the starting of study treatment, 8 months post the starting of study treatment, 14 months post the starting of study treatment
  4. description
    Patient reported neurotoxicity symptoms as measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less neurotoxicity.
    measure
    Patient-reported Neurotoxicity
    time Frame
    Prior to study treatment (baseline), 4 weeks post the starting of study treatment, 10-11 weeks post the starting of study treatment, 8 months post the starting of study treatment, 14 months post the starting of study treatment.
  5. description
    Patient reported quality of life as measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Endometrium Cancer subscale (16 items). Each item in the FACT-En TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The FACT-En TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-En TOI items provide valid answers and all of the component subscales have valid scores. The FACT-En TOI score ranges 0-120 with a large score suggests better QOL
    measure
    Patient-reported Quality of Life
    time Frame
    Prior to study treatment (baseline), 4 weeks post the starting of study treatment, 10-11 weeks post the starting of study treatment, 8 months post the starting of study treatment, 14 months post the starting of study treatment
Full study description
brief Summary
This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether pelvic radiation therapy alone is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.
detailed Description
PRIMARY OBJECTIVES: I. To determine if treatment with vaginal cuff brachytherapy followed by three cycles of chemotherapy reduces the rate of recurrence or death (i.e. increases recurrence-free survival) when compared to pelvic radiation therapy. SECONDARY OBJECTIVES: I. To compare survival between the two treatment groups. II. To compare patterns of failure between the two treatment groups. III. To compare physical functioning, fatigue and neurotoxicity between the two treatment groups. IV. To examine associations between primary comorbid illnesses and obesity on survival, fatigue and physical functioning. V. To evaluate the psychometric properties (such as construct validity, reliability, sensitivity to treatment and responsiveness over time) of the Patient-Reported-Outcomes Measurement Information System (PROMIS) Fatigue Short form 1, and to evaluate fatigue measurement equivalence between women with endometrial cancer and age-matched women from the general United States (US) population. TERTIARY OBJECTIVES: I. To evaluate the ability of gene expression signatures in early stage endometrial cancer to predict recurrence and to explore the association between gene expression signatures in early stage endometrial cancer and clinical characteristics and outcome. II. To bank whole blood specimens for future research. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments. ARM II: Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter for up to 5 years.
Source references
references
  1. citation
    Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ, Rutherford T, Spirtos NM, Terada K, Anderson PR, Brewster WR, Small W, Aghajanian CA, Miller DS. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019 Jul 20;37(21):1810-1818. doi: 10.1200/JCO.18.01575. Epub 2019 Apr 17.
    pmid
    30995174
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e402d95bd75c20b9153b
      requested nct id
      NCT00807768
      primary nct id
      NCT00807768
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      b6710ff985346052b92134d475e1f6f9b2a9bbb7c87d1a3d83093a5921deff50
      payload sha256
      663a48075540098ac263aa39423a834807554f117b0d3315015edc01b3fa1d5b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e402d95bd75c20b9153b
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00807768
      occurrences
      1. context exact
        NCT00807768
        end
        11
        exact text
        NCT00807768
        start
        0
      offset unit
      unicode_code_points
      query cond
      Vaginal Cancer
      query disease state id
      ds-vaginal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vaginal-cancer-000.json
      source file sha256
      b6710ff985346052b92134d475e1f6f9b2a9bbb7c87d1a3d83093a5921deff50
      source json pointer
      /studies/20/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c549e1c55ea9a5561c0c972b53100de088bdf2d4447c1f62964557d3597bd4ed

    Preserved source evidence · Not medical advice